Cargando…

SEC coupled with in-line multiple detectors for the characterization of an oncolytic Coxsackievirus

V937 is an oncolytic virus immunotherapy clinical drug candidate consisting of a proprietary formulation of Coxsackievirus A21 (CVA21). V937 specifically binds to and lyses cells with over-expressed ICAM-1 receptors in a range of tumor cell types and is currently in phase I and II clinical trials. I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deng, James Z., Rustandi, Richard R., Swartz, Andrew, Shieh, Yvonne, Baker, Jack B., Vlasak, Josef, Wang, Shiyi, Loughney, John W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718657/ https://www.ncbi.nlm.nih.gov/pubmed/35024440 http://dx.doi.org/10.1016/j.omto.2021.12.009

Ejemplares similares

Reverse-Phase Ultra-Performance Chromatography Method for Oncolytic Coxsackievirus Viral Protein Separation and Empty to Full Capsid Quantification
por: Deng, James Z., et al.
Publicado: (2022)

Coxsackievirus B3—Its Potential as an Oncolytic Virus
por: Geisler, Anja, et al.
Publicado: (2021)

Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines
por: Lin, Yanzhen, et al.
Publicado: (2018)

Development of Group B Coxsackievirus as an Oncolytic Virus: Opportunities and Challenges
por: Liu, Huitao, et al.
Publicado: (2021)

2-Deoxyglucose, an Inhibitor of Glycolysis, Enhances the Oncolytic Effect of Coxsackievirus
por: Vorobyev, Pavel O., et al.
Publicado: (2022)

Glutathione affinity chromatography for the scalable purification of an oncolytic virus immunotherapy from microcarrier cell culture
por: Swartz, Andrew R., et al.
Publicado: (2023)

Prior Exposure to Coxsackievirus A21 Does Not Mitigate Oncolytic Therapeutic Efficacy
por: Burnett, William J., et al.
Publicado: (2021)

Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma
por: Okamura, Koji, et al.
Publicado: (2022)

Development of a microchip capillary electrophoresis method for determination of the purity and integrity of mRNA in lipid nanoparticle vaccines
por: Raffaele, Jessica, et al.
Publicado: (2021)

Application Route and Immune Status of the Host Determine Safety and Oncolytic Activity of Oncolytic Coxsackievirus B3 Variant PD-H
por: Hazini, Ahmet, et al.
Publicado: (2021)

Enhanced genomic stability of new miRNA-regulated oncolytic coxsackievirus B3
por: Liu, Huitao, et al.
Publicado: (2022)

Coxsackievirus Type B3 Is a Potent Oncolytic Virus against KRAS-Mutant Lung Adenocarcinoma
por: Deng, Haoyu, et al.
Publicado: (2019)

Development of an imaged capillary isoelectric focusing method for characterizing the surface charge of mRNA lipid nanoparticle vaccines
por: Loughney, John W., et al.
Publicado: (2019)

Oncolytic immunotherapy for the treatment of non-muscle invasive bladder cancer using intravesical coxsackievirus A21
por: Annels, Nicola E, et al.
Publicado: (2015)

MicroRNA Modification of Coxsackievirus B3 Decreases Its Toxicity, while Retaining Oncolytic Potency against Lung Cancer
por: Liu, Huitao, et al.
Publicado: (2020)

MicroRNA Modification of Coxsackievirus B3 Decreases Its Toxicity, while Retaining Oncolytic Potency against Lung Cancer
por: Liu, Huitao, et al.
Publicado: (2021)

Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21
por: Müller, Louise M. E., et al.
Publicado: (2019)

Extremely Low Organ Toxicity and Strong Antitumor Activity of miR-34-Regulated Oncolytic Coxsackievirus B3
por: Jia, Yang, et al.
Publicado: (2019)

Coxsackievirus Group B3 Has Oncolytic Activity against Colon Cancer through Gasdermin E-Mediated Pyroptosis
por: Zhang, Yejia, et al.
Publicado: (2022)

Etymologia: Coxsackievirus
Publicado: (2012)

COXSACKIEVIRUSES (PICORNAVIRIDAE)
por: Pozzetto, Bruno, et al.
Publicado: (1999)

Dimeric SecA Couples the Preprotein Translocation in an Asymmetric Manner
por: Tang, Ying, et al.
Publicado: (2011)

Coxsackievirus A11 is an immunostimulatory oncolytic virus that induces complete tumor regression in a human non-small cell lung cancer
por: Sakamoto, Akira, et al.
Publicado: (2023)

Engineering Oncolytic Coxsackievirus A21 with Small Transgenes and Enabling Cell-Mediated Virus Delivery by Integrating Viral cDNA into the Genome
por: Sam, Miranda, et al.
Publicado: (2023)

Let’s talk about Secs: Sec61, Sec62 and Sec63 in signal transduction, oncology and personalized medicine
por: Linxweiler, Maximilian, et al.
Publicado: (2017)

Combination of a novel oncolytic immunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model
por: Shafren, Darren, et al.
Publicado: (2014)

Stepwise gating of the Sec61 protein-conducting channel by Sec63 and Sec62
por: Itskanov, Samuel, et al.
Publicado: (2021)

Phase I/II storm study: Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21, in advanced cancer patients
por: Pandha, Hardev, et al.
Publicado: (2015)

Functional profiling of Covid 19 vaccine candidate by flow virometry
por: Prout, Ashley, et al.
Publicado: (2022)

SEC Reporting
por: USA, BDO
Publicado: (2020)

Development and Characterization of an In Vitro Cell-Based Assay to Predict Potency of mRNA–LNP-Based Vaccines
por: Patel, Nisarg, et al.
Publicado: (2023)

A Stereoselective Inverting sec-Alkylsulfatase for the Deracemization of sec-Alcohols
por: Schober, Markus, et al.
Publicado: (2011)

Sec12 Binds to Sec16 at Transitional ER Sites
por: Montegna, Elisabeth A., et al.
Publicado: (2012)

Rhombencephalitis and Coxsackievirus A16
por: Goto, Kazuna, et al.
Publicado: (2009)

Coxsackievirus Infection and Associated Diseases
por: Nekoua, Magloire Pandoua, et al.
Publicado: (2022)

CEACAM-1 promotes myocardial injury following coxsackievirus infection by regulating the coxsackievirus-adenovirus receptor
por: Zhang, Zaiyong, et al.
Publicado: (2019)

secA, secD, secF, yajC, and yidC contribute to the adhesion regulation of Vibrio alginolyticus
por: Guo, Lina, et al.
Publicado: (2017)

How does Sec63 affect the conformation of Sec61 in yeast?
por: Bhadra, Pratiti, et al.
Publicado: (2021)

Oncolytic immunotherapy: multiple mechanisms of oncolytic peptides to confer anticancer immunity
por: Tang, Tianyu, et al.
Publicado: (2022)

Inhibition of coxsackievirus infection in cardiomyocytes by small dsRNA targeting its cognate coxsackievirus adenovirus receptor
por: Sharma, Mirnalini, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_tp0g8tehoth6234u0ja05h7rvk